STOCK TITAN
  1. Home
  2. Sec-filings
  3. MGNX
  4. [8-K] MACROGENICS INC Reports Material Event

Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

MacroGenics, Inc. reported that board member Karen Ferrante, M.D. has decided to resign from its board of directors. She notified the board on July 1, 2026, with her resignation effective September 1, 2026. The company states that her decision is for personal reasons and not due to any disagreement related to operations, policies, or practices. MacroGenics publicly thanked Dr. Ferrante for her contributions to the company.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Resignation notice date July 1, 2026 Date Karen Ferrante, M.D. notified the board
Resignation effective date September 1, 2026 Effective date of departure from MacroGenics board
board of directors financial
"provided notice to the board of directors (the “Board”) of MacroGenics, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Global Select Market financial
"Common Stock, par value $0.01 per share | MGNX | Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What board change did MacroGenics (MGNX) disclose in this 8-K?
MacroGenics disclosed that board member Karen Ferrante, M.D. plans to resign from its board of directors, effective September 1, 2026. She notified the board on July 1, 2026, and the company expressed appreciation for her service.

Why is Karen Ferrante, M.D. resigning from the MacroGenics (MGNX) board?
Karen Ferrante, M.D. is resigning from the MacroGenics board for personal reasons, according to the company. The filing specifies that her decision is not due to any disagreement regarding the company’s operations, policies, or practices.

When will Karen Ferrante’s resignation from MacroGenics (MGNX) become effective?
Her resignation from the MacroGenics board becomes effective September 1, 2026. She provided notice of her decision on July 1, 2026, giving the company time to manage the transition and consider future board composition.

Does this MacroGenics (MGNX) 8-K include any financial or earnings data?
This 8-K centers on a board resignation and does not present earnings or financial performance data. The main disclosure is the timing and nature of Karen Ferrante’s departure from the MacroGenics board of directors.
0001125345FALSE00011253452026-07-012026-07-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K
 
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  July 1, 2026
 
MACROGENICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware001-3611206-1591613
(State or Other Jurisdiction of Incorporation)
(Commission
File Number)
(IRS Employer
 Identification No.)
9704 Medical Center Drive
Rockville,Maryland20850
(Address of Principal Executive Offices)(Zip Code)


Registrant's telephone number, including area code:  (301) 251-5172
 
Not applicable 
(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareMGNXNasdaq Global Select Market
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”) of her decision to resign from the Board, effective September 1, 2026. Dr. Ferrante’s decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Ferrante for her many contributions to the Company.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 






Date: July 8, 2026
MACROGENICS, INC.

By: /s/ Jeffrey Peters
      Jeffrey Peters
      Senior Vice President, General Counsel and Corporate Secretary





Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents